|Bid||0.00 x 3200|
|Ask||0.00 x 1100|
|Day's Range||59.95 - 60.84|
|52 Week Range||45.76 - 68.34|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 05, 2020|
|Forward Dividend & Yield||1.80 (2.97%)|
|Ex-Dividend Date||Oct. 01, 2020|
|1y Target Est||73.69|
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.
Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.